IRCT20200623047902N26尚未招募未知
Bioequivalence study of Dimethyl fumarate capsule 240 mg manufactured by Alborzzagros versus originator brand in healthy volunteers in the fasted condition
Alborz Zagros company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to dimethyl fumarate
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Dimethyl Fumarate 240-mg capsule in comparison with Dimethyl Fumarate brand Capsule (Tecfidera®).Bioequivalence study.IRCT20200407046981N27Avicenna Pharmaceutical Company24
尚未招募
不适用
In-vivo Bioequivalence Test of Dimethyl fumarate Capsules with brand drug (TECFIDERA® 240 mg, Biogen, Germany)Bioequivalence Study.IRCT20200105046010N43ABIDI Pharmaceutical Company24
招募中
3 期
Efficacy of dimethyl fumarate administration vs placebo on neurosurgical brain induced injury measured by S100 beta protein concentration and performance (Karnofsky scale) among glioblastoma multiform patientGliobalstom multiforme.Malignant neoplasm of brain, unspecifiedC71.9IRCT20200226046624N1Tehran University of Medical Sciences72
招募中
1 期
Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trialAdrenomyeloneuropathyCTIS2023-506795-27-00Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBE40
招募中
2 期
Evaluation of efficacy of Dimethyl Fumarate in strokeIRCT20180224038841N1Tehran University of Medical Sciences32